Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart Patients' cholesterol battle: new study reveals hidden barriers

NCT ID NCT06897566

Knowledge-focused Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study in Egypt examined 1,000 adults with heart disease to see how many reached their LDL cholesterol targets and what got in the way. Participants provided a fasting lipid profile, and researchers looked for patterns and barriers. The goal is to find better ways to help patients manage cholesterol and prevent further heart problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors understand why patients struggle to reach cholesterol targets and improve treatment strategies for heart disease.
What could go wrong
This is an observational study, not a treatment trial. It identifies problems but does not test a solution, so direct patient benefits are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,000 people

The number who actually took part.

Started

Sep 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with established ASCVD with indication for high-intensity statin for a period 6 months This includes patients with coronary artery disease, peripheral arterial disease, cerebrovascular disease.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients presenting to cardiology department/ outpatient clinic. * Established ASCVD and eligible for high intensity statins for at least six-months. * Age between18-to-80y. Exclusion Criteria: * Refusal to participate in the survey. * Recent diagnosis of ASCVD with indication to high intensity statins for a period \< six-months. * Patients with medical limitation or contraindications to statins therapy. * Patients with documented diagnosis of homozygous familial hypercholesterolemia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease coronary artery disorder statin toxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease LDL level Statin adverse reaction

Contacts and locations

Locations

  • Faculty of Medicine Cairo University

    Cairo, Egypt

  • Faculty of Medicine, Cairo University

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.